Author

M. Dittmar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

J. S. Lee· 3 shared K. Whig· 3 shared M. Li· 3 shared S. Cherry· 3 shared D. Schultz· 2 shared J. Miller· 2 shared K. Ayyanathan· 2 shared B. Kamalia· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. S. Lee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Evolutionary arms race between SARS-CoV-2 and interferon signaling via dynamic interaction with autophagy.

J. S. Lee, M. Dittmar, J. Miller, M. Li, K. Ayyanathan, M. B. Ferretti, J. Hulahan, K. Whig, Z. Etwebi, T. Griesman, D. C. Schultz, S. Cherry

This study identifies how SARS-CoV-2 evolves to counteract host interferon signaling through interactions with autophagy pathways.

bioRxiv · Nov 13, 2023 · PreprintMicrobiology

Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

D. Schultz, R. Johnson, K. Ayyanathan, J. Miller, K. Whig, B. Kamalia, M. Dittmar, S. Weston, H. Hammond, C. Dillen, L. Castellana, J. S. Lee, M. Li, E. M. Lee, S. Constant, , S. Cherry

The paper screens 18,000 drugs for antiviral activity against SARS-CoV-2, identifies synergistic combinations of pyrimidine biosynthesis inhibitors and nucleoside analogs, and validates their efficacy in vitro and in vivo.

bioRxiv · Jun 24, 2021 · PreprintMicrobiology

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2

M. Dittmar, J. S. Lee, K. Whig, E. Segrist, M. Li, K. Jurado, K. Samby, H. Ramage, D. Schultz, S. Cherry

The paper screens FDA-approved drugs against SARS-CoV-2 in different cell types, identifying three FDA-approved antivirals with potential for clinical use.

bioRxiv · Jun 19, 2020 · PreprintMicrobiology